COMMUNIQUÉS West-GlobeNewswire

InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and Venereology Congress

25/09/2024 - 13:30

JENA, Germany, Sept. 25, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the e-poster [...]

Amedisys has earned the 2023 SHPBest™ Patient Satisfaction Awards

25/09/2024 - 13:30

BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care centers recognized by [...]

23andMe Launches New Genetic Report on Likelihood of Frequent Emotional Eating

25/09/2024 - 13:30

Provides 23andMe+ Premium members with insight into their likelihood of experiencing emotional eating based on their genetics SUNNYVALE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co., (Nasdaq: ME), a [...]

Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024

25/09/2024 - 13:30

BEDFORD, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development [...]

Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104

25/09/2024 - 13:30

Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025 PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, [...]

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

25/09/2024 - 13:08

Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration Equivalent potency to risankizumab with similar binding affinity and epitope [...]

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

25/09/2024 - 13:07

$185+ million in incremental orders for ACAM2000® and VIGIV to be delivered in 2024 and 2025 GAITHERSBURG, Md., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured [...]

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

25/09/2024 - 13:00

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings to date Financing co- [...]

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

25/09/2024 - 11:01

Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio® Sales of Entyvio (vedolizumab) were about $5.4 billion globally in the [...]

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

25/09/2024 - 11:00

Alvotech is one of two companies known to have initiated a global or multi-country confirmatory patient study for a biosimilar candidate to Entyvio ® Sales of Entyvio (vedolizumab) were about $5.4 billion globally in [...]

Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021

25/09/2024 - 09:00

Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR)-guided [...]

New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

25/09/2024 - 07:00

ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type ZORYVE was safe and well tolerated [...]

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic

25/09/2024 - 07:00

Genespire raises €46.6 million (~$52 million) in a Series B round to advance its first pediatric in-vivo gene therapy into the clinic One of the largest private Italian Biotech company financings to date Financing co- [...]

Junshi Biosciences Announces European Commission Approval for Marketing of Toripalimab

25/09/2024 - 05:29

SHANGHAI, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]

Lifeward Launches Direct Sales of AlterG Product Line in Germany

24/09/2024 - 23:00

Direct sales of AlterG products through the Lifeward GmbH sales team expected to improve margins and increase AlterG revenues in Germany, accelerating Lifeward’s path to profitability MARLBOROUGH, Mass. and BERLIN and [...]

Kairos Pharma Enters Agreement with PreCheck Health Services to Develop Biomarkers to Identify Patients Responsive to ENV105 to Target Cancer Drug Resistance in Prostate and Lung Cancer Patients

24/09/2024 - 22:20

LOS ANGELES, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces a groundbreaking collaboration with PreCheck Health Services Inc., a CLIA- [...]

Precision Optics Corporation Schedules Fourth Quarter and Fiscal Year 2024 Conference Call for Monday, September 30, 2024

24/09/2024 - 22:15

GARDNER, Mass., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (Nasdaq: POCI) (the "Company"), a leading designer and manufacturer of advanced optical instruments for the medical and defense/ [...]

LifeMD® Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

24/09/2024 - 22:05

NEW YORK, Sept. 24, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the [...]

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

24/09/2024 - 22:05

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with [...]